Moderna Inc (MRNA) stock saw a decline, ending the day at $69.86 which represents a decrease of $-2.13 or -2.96% from the prior close of $71.99. The stock opened at $72.19 and touched a low of $69.82 ...
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...
Even as the Covid wave in Florida continues, Gov. Ron DeSantis’ administration is once again advising against the mRNA ...
A German study published in July 2024 did not find that mRNA COVID-19 vaccines damaged children’s immune systems, contrary to ...
Frustrated when Brazil could not get COVID vaccines, two Brazilian doctors (who have been best friends since college) decided ...
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) today and set a price target of $75.00. The ...
Based on the high rate of global immunity and currently available data, the State Surgeon General advises against the use..." ...
(Reuters) -British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza ...
New York, New York-- (Newsfile Corp. - September 18, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Moderna, Inc. (NASDAQ: MRNA) between January 18 ...
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients in Phase 1 trial
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...
Florida health officials are raising alarms about the safety of the newest versions of mRNA COVID-19 vaccines, advising ...
Primrose Bio, a San Diego biotech company, has begun a partnership to jointly develop and market products for mRNA medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback